My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.660 -0.040 (-2.35%)

Official Closing Price Updated: 8:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 Next >

Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying ↗

January 03, 2024

The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 29, 2023

Via Benzinga

3 Penny Stocks to Buy for the Next Bull Run ↗

November 11, 2023

While penny stocks to buy represent a terribly risky venture, it’s possible that maybe one of these ideas could skyrocket.

Via InvestorPlace

Lineage Cell Therapeutics: Q3 Earnings Insights ↗

November 09, 2023

Via Benzinga

Earnings Preview: Lineage Cell Therapeutics ↗

November 08, 2023

Via Benzinga

Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks ↗

October 17, 2023

Here are the best longevity stocks to consider. Each stock listed comes with their unique reasons to buy them.

Via InvestorPlace

Lineage Cell Therapeutics Earnings Preview ↗

August 09, 2023

Via Benzinga

Lineage Cell Therapeutics: Q1 Earnings Insights ↗

May 11, 2023

Via Benzinga

Lineage Cell Therapeutics's Return On Capital Employed Overview ↗

March 14, 2023

Via Benzinga

EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics ↗

September 06, 2023

Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and...

Via Benzinga

Why DLocal Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket ↗

August 16, 2023

Gainers

Via Benzinga

Lineage Cell Therapeutics' Lung Cancer Vaccine: Initial Data Reveals Modest, Durable Immune Response ↗

July 24, 2023

Lineage Cell Therapeutics Inc (NYSE: LCTX) and Cancer Research UK revealed primary and secondary endpoint results from the recently completed clinical study of VAC2 in advanced non-small

Via Benzinga

Harley-Davidson, Sportsman's Warehouse And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

April 13, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Preview: Lineage Cell Therapeutics's Earnings ↗

March 08, 2023

Via Benzinga

Earnings Scheduled For August 10, 2023 ↗

August 10, 2023

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.

Via Benzinga

3 Penny Stocks to Buy During Market Downturns ↗

April 10, 2023

If you're looking for penny stocks to buy that can weather economic turmoil, these should make the cut due to their strong fundamentals.

Via InvestorPlace

EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology ↗

February 22, 2023

Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive option and license agreement with Eterna Therapeutics Inc for beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell...

Via Benzinga

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies ↗

January 25, 2023

BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development.

Via Benzinga

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

Earnings Preview: Lineage Cell Therapeutics ↗

November 09, 2022

Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗

November 02, 2022

Upgrades

Via Benzinga

A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field

October 14, 2022

By David Willey, Benzinga

Via News Direct

121 Stocks That Hit Their 52-Week Low ↗

October 14, 2022

New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.

Via Benzinga

A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field ↗

October 13, 2022

Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems.

Via Benzinga

EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility ↗

October 03, 2022

Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California.

Via Benzinga

The Three Best Anti-Aging Stocks to Buy in September ↗

September 19, 2022

These three anti-aging stocks could see recovery ahead. ATHX, LCTX, and UBX can make great long-term investments

Via InvestorPlace

Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed ↗

September 07, 2022

According to data from Benzinga Pro, during Q2, Lineage Cell Therapeutics's (AMEX:LCTX) reported sales totaled $4.55 million. Despite a 4.38% increase in earnings, the company posted a loss of $6.78...

Via Benzinga

Recap: Lineage Cell Therapeutics Q2 Earnings ↗

August 11, 2022

Lineage Cell Therapeutics (AMEX:LCTX) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug ↗

July 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗

June 14, 2022

Upgrades

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.